Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
about
Arginine Vasopressin and Copeptin in PerinatologyG-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and preventionDiabetes insipidus: The other diabetesBiomarkers in community-acquired pneumonia: a state-of-the-art reviewAmerican Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes.A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus.Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study[Etiological diagnosis of central diabetes insipidus: about 41 cases].Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.Differences in autonomic balance in patients with cardioinhibitory and vasodepressor type of reflex syncope during head-up tilt test and active standing.Orthostatic Changes in Hemodynamics and Cardiovascular Biomarkers in Dysautonomic PatientsProcalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis studyCopeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhageInhibition of Ectopic Arginine Vasopressin Production by Phenytoin in the Small Cell Lung Cancer Cell Line Lu-165Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.Copeptin levels remain unchanged during the menstrual cycle.Risk stratification in emergency patients by copeptinModern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients.Pathophysiology of copeptin in kidney disease and hypertensionThe Circadian Rhythm of Copeptin, the C-Terminal Portion of Arginine Vasopressin.Copeptin concentration in cord blood in infants with early-onset sepsis, chorioamnionitis and perinatal asphyxia.Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patientsThe role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency departmentEvaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension.Copeptin as a marker of relative arginine vasopressin deficiency after pediatric cardiac surgery.MDMA enhances emotional empathy and prosocial behaviorPredictors of autosomal dominant polycystic kidney disease progressionCopeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke.Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage.Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients.Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney diseaseCopeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness
P2860
Q26741093-632D2F4E-B5B9-4104-8618-D76AF5AAAB4FQ26744192-4A55865D-C505-4D04-8561-D1FEE16B3DC7Q26767266-60A6AF51-D982-4D24-BEFC-3242929F874AQ27026995-96A54A84-D346-4760-9019-FE4FB7208F39Q30277654-F22705A2-9176-4D8C-BE6B-844ACDB6B017Q30434636-A35A83A5-73FC-47B0-B08F-6DCCD5A824CEQ30982488-84624860-B952-4A6D-A6C3-C0ACFEA1F406Q31131029-1D631A5E-DA97-4BA5-82AE-9268B6CA40CBQ31131612-5605ABFA-F214-464A-844D-1174AE3B7276Q31154416-3E572380-2DD8-4039-89F8-A21BDD84FED8Q33160964-CC7305E5-4763-45D8-84FE-24D3885F39CAQ33165831-7A9429AF-231A-4CC7-9A14-E5ED847BEA72Q33290142-7A661ED5-40E6-48D2-BA6F-F02B44B28FAFQ33526184-39A97637-0BB2-4189-BAAD-291EBA1FD538Q33530066-CCA05F9F-FC15-4064-9E6E-411A8E79FE66Q33588084-1D811897-624F-4C4C-B696-D8E930709306Q33611588-286DB32D-EB78-415D-9A21-595ED2E1D49BQ33660700-CDBD0DA1-7F9E-43A1-B207-8AF0A59A7AABQ33670687-9D4A6EBA-2F83-4ECD-9839-02280C934018Q33740059-158E8288-79E1-43DE-A130-E23ADAC159CAQ33743502-ED0C1C1D-E52E-4EF8-9D05-0D7353679F2CQ33792317-84D00B4F-F111-4CDB-8AD5-52E3EDFDA706Q33800762-0AAFA42B-A92E-472A-A1BC-1D12F23BD4A8Q33906174-97375201-C555-4536-BAA6-968685FDE196Q33932812-A7E7B366-3F1A-48D3-9891-52E8605AB722Q34026975-0D0727D4-A699-4A3F-B893-4A84355CD578Q34094366-AB966094-E871-49AA-8AD0-8E2BD5769681Q34124758-40882012-AA35-4A87-AFCC-CB19F52D5227Q34134378-F65B7C8E-749B-425E-88E9-3B6AC9E42D0EQ34241396-53A4F3F0-6A6B-4EBC-9250-FCE3370A01B9Q34248479-D268D17F-472A-4179-B8FE-8F9942C85578Q34307867-9C200CB4-0981-4CFF-8B29-1542EBCEAF93Q34375625-C0EEDD24-33F7-4F41-B987-21E8E719AF51Q34427678-1A17DBDA-5F03-4D6B-B582-9BC9586CA3A3Q34464946-16E7644D-329C-4F4A-B63D-4340E4E7DEE4Q34551235-5D32C84B-BDB1-4D28-A185-D3A86DDE61FFQ34558232-368B1A28-C3B9-447E-8D9B-6CF4CB0D6DE0Q34639667-CACBC432-7222-497F-9284-FD8527C8BEBAQ34726918-62709419-539C-45B2-9ADC-FE946C19B53BQ34983634-1539CF38-5666-41DC-9DC8-6F6D9EEE73BC
P2860
Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Assay for the measurement of c ...... the precursor of vasopressin.
@en
Assay for the measurement of c ...... the precursor of vasopressin.
@nl
type
label
Assay for the measurement of c ...... the precursor of vasopressin.
@en
Assay for the measurement of c ...... the precursor of vasopressin.
@nl
prefLabel
Assay for the measurement of c ...... the precursor of vasopressin.
@en
Assay for the measurement of c ...... the precursor of vasopressin.
@nl
P2093
P1433
P1476
Assay for the measurement of c ...... the precursor of vasopressin.
@en
P2093
Andreas Bergmann
Christine Alonso
Joachim Struck
Nils G Morgenthaler
P304
P356
10.1373/CLINCHEM.2005.060038
P407
P577
2005-11-03T00:00:00Z